NewAmsterdam Pharma Co N.V.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

NAMS$19.18+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	For the three months ended September 30,		For the nine months ended September 30,
	2026	2025	2026	2025
(In thousands of USD, except per share amounts)
Revenue	19,164	348	25,905	22,471
Operating expenses:
Research and development expenses	39,357	30,971	119,039	103,238
Selling, general and administrative expenses	23,995	24,521	74,338	78,937
Total operating expenses	63,352	55,492	193,377	182,175
Operating loss	(44,188)	(55,144)	(167,472)	(159,704)
Other income (expense):
Interest income, net	5,187	6,713	16,647	21,119
Fair value change – earnout	—	—	—	3,992
Fair value change – warrants	23,118	(23,792)	24,505	(7,440)
Foreign exchange gains/(losses)	(299)	218	(2,438)	13,137
Loss before tax	(16,182)	(72,005)	(128,758)	(128,896)
Income tax expense	1,207	—	1,207	—
Loss for the period	(17,389)	(72,005)	(129,965)	(128,896)
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax	(241)	313	(1,173)	173
Total comprehensive loss for the period, net of tax	(17,630)	(71,692)	(131,138)	(128,723)
Net loss per ordinary share
Basic and diluted	$(0.14)	$(0.61)	$(1.06)	$(1.09)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.